Financials in USD. Standardized financial statements.
A compact view of how Evofem Biosciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $20.18M | $19.36M | $18.22M | $16.84M | $8.24M | $446,000 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +4.2% | +6.3% | +8.2% | +104.2% | +1748.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $5.12M | $3.83M | $6.51M | $4.42M | $4.05M | $1.65M | $905,000 | $262,000 | $244,000 | $69,094 |
| Gross Profit? | $15.07M | $15.53M | $11.71M | $12.42M | $4.19M | -$1.20M | -$905,000 | -$262,000 | -$244,000 | -$69,094 |
| Gross Margin? | +74.7% | +80.2% | +64.3% | +73.8% | +50.8% | -269.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $13.63M | $23.20M | $29.55M | $96.55M | $170.99M | $102.42M | $51.84M | $77.38M | $35.44M | $11.97M |
| Operating Income? | $1.44M | -$7.68M | -$17.85M | -$84.12M | -$166.80M | -$103.62M | -$52.74M | -$77.64M | -$35.69M | -$12.04M |
| EBITDA? | $2.06M | -$6.92M | -$16.07M | -$82.08M | -$165.78M | -$141.12M | -$79.12M | -$125.45M | -$105.06M | -$11.91M |
| Income Before Tax | $393,000 | -$8.86M | $53.00M | -$76.65M | -$205.18M | -$142.31M | -$80.03M | -$125.71M | -$105.30M | -$13.02M |
| Income Tax Expense | $2,000 | $0 | $17,000 | $44,000 | $17,000 | $4,000 | $4,000 | $2,000 | $3,000 | $0 |
| Net Income? | $391,000 | -$8.86M | $52.98M | -$76.70M | -$205.19M | -$142.31M | -$80.03M | -$125.71M | -$105.31M | -$13.02M |
| EPS? | $0.00 | $-0.09 | $10.36 | $-164.59 | $-2962.49 | $-3973.23 | $-3730.27 | $-10763.01 | $-85613.82 | $-10612.22 |
| Diluted EPS? | $0.00 | $-0.09 | $0.05 | $-164.59 | $-2962.49 | $-3973.23 | $-3730.27 | $-10763.01 | $-85613.82 | $-10612.22 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality